Charles Zhu
Stock Analyst at Guggenheim
(2.75)
# 1,853
Out of 5,182 analysts
19
Total ratings
52.94%
Success rate
34.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Buy | $10 → $12 | $26.33 | -54.42% | 4 | Oct 24, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $22 | $25.15 | -12.52% | 1 | Jun 18, 2025 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $3.05 | +293.44% | 4 | Nov 7, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $104.04 | -46.17% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $4.99 | +340.88% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $36.61 | -28.97% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $29.48 | +8.55% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $28.56 | -50.98% | 2 | May 5, 2022 |
Tango Therapeutics
Oct 24, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $26.33
Upside: -54.42%
Crescent Biopharma
Jun 18, 2025
Initiates: Outperform
Price Target: $22
Current: $25.15
Upside: -12.52%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $3.05
Upside: +293.44%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $104.04
Upside: -46.17%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $4.99
Upside: +340.88%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $36.61
Upside: -28.97%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $29.48
Upside: +8.55%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $28.56
Upside: -50.98%